Intas Pharmaceuticals

Intas Pharmaceuticals is one of the largest privately held pharmaceutical companies in India, generating over $1 billion in annual revenue, with 60% derived from international markets. The company operates in 70 countries, and more than 80% of its export revenue comes from the US, UK, and EU. Intas has over 10 manufacturing facilities that are compliant with global regulatory standards, producing a diverse range of dosage forms, including oral solids, liquids, injectables, and biosimilars. Employing around 12,000 people globally, including over 800 scientists, Intas invests approximately 6% of its sales in research and development. The company's R&D efforts focus on generics, biosimilars, and innovative drug delivery systems, making it a leader in the biosimilars market in India and the first Indian firm to launch a biosimilar in the EU. Intas's expertise in oncology products for solid tumors and hematological malignancies further underscores its commitment to addressing critical health challenges. The company is headquartered in Ahmedabad, India, and is supported by prominent financial investors, Temasek and ChrysCapital.